Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?

Expert Opin Drug Saf. 2020 Aug;19(8):923-926. doi: 10.1080/14740338.2020.1796964. Epub 2020 Jul 27.

Authors

Siddhartha Yadav¹, Karthik V Giridhar¹, Jodi Taraba², Roberto Leon-Ferre¹, Kathryn J Ruddy¹

Affiliations

¹ Department of Oncology, Mayo Clinic , Rochester, MN, USA.
² Department of Pharmacy Services, Mayo Clinic , Rochester, MN, USA.

PMID: 32716212
DOI: 10.1080/14740338.2020.1796964

No abstract available

Keywords: Breast Neoplasms; chemotherapy; male breast cancer; therapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacology
Breast Neoplasms, Male / drug therapy*
Breast Neoplasms, Male / pathology
Decision Making
Humans
Male
Sex Factors

Substances

Antineoplastic Agents